Nanoparticle-based medicines in clinical cancer therapy
S Wang, K Cheng, K Chen, C Xu, P Ma, G Dang… - Nano Today, 2022 - Elsevier
Anti-cancer drugs with various mechanisms emerge in succession, but most of free
therapeutics are accompanied by some disadvantages, such as poor safety and …
therapeutics are accompanied by some disadvantages, such as poor safety and …
PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases
HO Alsaab, FD Alharbi, AS Alhibs, NB Alanazi… - Pharmaceutics, 2022 - mdpi.com
Research on the use of biodegradable polymers for drug delivery has been ongoing since
they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering …
they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering …
Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic
In the last decade, investigators have put significant efforts to develop several diagnostic
and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic …
and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic …
Current perspectives on taxanes: Focus on their bioactivity, delivery and combination therapy
J Škubník, V Pavlíčková, T Ruml, S Rimpelová - Plants, 2021 - mdpi.com
Taxanes, mainly paclitaxel and docetaxel, the microtubule stabilizers, have been well known
for being the first-line therapy for breast cancer for more than the last thirty years. Moreover …
for being the first-line therapy for breast cancer for more than the last thirty years. Moreover …
PLGA's plight and the role of stealth surface modification strategies in its use for intravenous particulate drug delivery
VV Sheffey, EB Siew, EEL Tanner… - Advanced …, 2022 - Wiley Online Library
Numerous human disorders can benefit from targeted, intravenous (IV) drug delivery.
Polymeric nanoparticles have been designed to undergo systemic circulation and deliver …
Polymeric nanoparticles have been designed to undergo systemic circulation and deliver …
Recent advances in PLGA based nanocarriers for drug delivery system: a state of the art review
The biomolecules in the clinical use being delivered by the conventional mode of delivery
often exhibit poor affinity. So, there is a need for a nanomedicine-based approach that could …
often exhibit poor affinity. So, there is a need for a nanomedicine-based approach that could …
Paclitaxel drug delivery systems: Focus on nanocrystals' surface modifications
Paclitaxel (PTX) is a chemotherapeutic agent that belongs to the taxane family and which
was approved to treat various kinds of cancers including breast cancer, ovarian cancer …
was approved to treat various kinds of cancers including breast cancer, ovarian cancer …
Lipid poly (ɛ-caprolactone) hybrid nanoparticles of 5-fluorouracil for sustained release and enhanced anticancer efficacy
Aims The present study aimed to develop and characterize poly (ɛ-caprolactone)(PCL)
based lipid polymer hybrid nanoparticles for sustained delivery and in-vitro anti-cancer …
based lipid polymer hybrid nanoparticles for sustained delivery and in-vitro anti-cancer …
Lipid-based nanoparticles in delivering bioactive compounds for improving therapeutic efficacy
In recent years, due to their distinctive and adaptable therapeutic effects, many natural
bioactive compounds have been commonly used to treat diseases. Their limited solubility …
bioactive compounds have been commonly used to treat diseases. Their limited solubility …
Development of sustained release baricitinib loaded lipid-polymer hybrid nanoparticles with improved oral bioavailability
Baricitinib (BTB) is an orally administered Janus kinase inhibitor, therapeutically used for the
treatment of rheumatoid arthritis. Recently it has also been approved for the treatment of …
treatment of rheumatoid arthritis. Recently it has also been approved for the treatment of …